COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI BUBU BHBH BLBL CICI HC QHC Q NZNZ COCO More..
 
Home   
Share  
  OutcomesOutcomes
  Global AdoptionAdoption
  Submit FeedbackFeedback
00.250.50.7511.251.51.752+Ramakrishnan (RCT)82%0.18 [0.04-0.79]hosp./ER2/7311/73Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment82%0.18 [0.04-0.79]2/7311/7382% improvementYu (RCT)17%0.83 [0.61-1.12]hosp./death59/692100/968Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment17%0.83 [0.61-1.12]59/692100/96817% improvementAll studies54%0.46 [0.11-1.96]61/765111/1,04154% improvement2 budesonide COVID-19 studiesc19budesonide.com 6/16/21Tau​2 = 0.85; I​2 = 74.3%; Z = 1.05 (p = 0.15)Lower RiskIncreased Risk
5/5
In Vitro Konduri et al., bioRxiv, doi:10.1101/2021.05.05.442779 (Preprint) (In Vitro) in vitro ProLung™-budesonide Inhibits SARS-CoV-2 Replication and Reduces Lung Inflammation
Details   In Vitro study and animal study showing that ProLung™-budesonide inhibits SARS-CoV-2 replication (results for budesonide were not provided). ProLung™-budesonide and budesonide significantly decreased lung inflammation. ProLung™-budesonide..
4/12
Late Yu et al., medRxiv, doi:10.1101/2021.04.10.21254672 (Preprint) hosp./death, ↓17.5%, p=0.24 Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial
Details   Interim results from the PRINCIPLE trial, 751 treated with budesonide starting a median of 6 days after symptom onset, showing lower hospitalization/death, and faster recovery with treatment.
2/8
Early Ramakrishnan et al., Lancet Respiratory Medicine, doi:10.1016/S2213-2600(21)00160-0 (preprint 2/8) (Peer Reviewed) hosp./ER, ↓81.8%, p=0.02 Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
Details   RCT with 73 budesonide patients and 73 control patients, showing significantly lower combined risk of an ER visit or hospitalization, and lower risk of no recovery at day 14.
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop to submit images   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit